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Enhancing tumor uptake of anticancer drugs is an important therapeutic goal, because
insufficient drug accumulation is now considered to be an important reason for unrespon-
siveness or resistance to antitumor therapy. Based on a mechanistic tumor uptake model
describing tumor exposure to molecules of different molecular size after bolus adminis-
tration, we have investigated the influence of the duration of intravenous administration
on tumor uptake. The model integrates empirical relationships between molecular size
and drug disposition (capillary permeability, interstitial diffusivity, available volume fraction,
and plasma clearance), together with a compartmental pharmacokinetics model and a
drug/target binding model. Numerical simulations were performed using this model for pro-
tracted intravenous drug infusion, a common mode of administration of anticancer drugs.
The impact of mode of administration on tumor uptake is described for a large range of
molecules of different molecular size. Evaluation was performed not only for the maximal
drug concentration achieved in the tumor, but also for the dynamic profile of drug concen-
tration. It is shown that despite a lower maximal uptake for a given dose, infusion allows
for a prolonged exposure of tumor tissues to both small- and large-sized molecules. More-
over, infusion may allow higher doses to be administered by reducing Cmax-linked toxicity,
thereby achieving a similar maximal uptake compared to bolus administration.
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INTRODUCTION
Solid tumors are characterized by important abnormalities in
tissue architecture and composition (1). These abnormalities
represent considerable obstacles for uptake and penetration of
antitumor drugs. Thus, tumor blood supply is often inefficient
and, consequently, drug delivery to the tumor is impaired. Also
the transvascular and interstitial transport of antitumor drugs
is impaired because of reduced transvascular pressure gradi-
ent, high interstitial fluid pressure (2), high packing density of
tumor cells (3), intercellular junctions (4), and altered compo-
sition of the extracellular matrix that increases frictional resis-
tance (5). These abnormalities compromise the tumor deliv-
ery of antitumor drugs of all molecular sizes, i.e., low molec-
ular weight drugs, macromolecular drugs, and nanoparticulate
drug formulations. In fact, transvascular and interstitial trans-
port of molecules is governed by flow (convection) and diffusion
from regions of high concentration to regions of lower con-
centration. For macromolecules diffusion is extremely slow, and
they are transported mainly by convection, that is, by stream-
ing of a flowing fluid (6). As regards low molecular weight
drugs, many of them show significant binding to plasma proteins,
which leads them to behave, functionally, like macromolecules.
Convection-driven transport, however, is often compromised in
solid tumors because of decrease or loss of the transvascular
pressure gradient.
Cytotoxic drugs (chemotherapeutics or antibodies mediat-
ing antibody-dependent cellular cytotoxicity or complement-
dependent cytotoxicity) can, at least in part, limit the negative
consequences of these effects. In fact, it has been proposed that
cytotoxic effector drugs that are administered repeatedly at reg-
ular intervals cause “peeling” of increasing numbers of tumor
cell layers until tumor regression is observed (2, 7, 8). Such a
mechanism of action is expected to suffer less from the nega-
tive consequences of an impaired interstitial transport and pen-
etration. The tumor cell layers that are eliminated are the most
proximal to the tumor vessels from which the drug extravasates.
Elimination of vessel-proximal tumor cell layers, however, may
stimulate proliferation and repopulation of more vessel-distant
tumor cells leading them to replace the cells that have been elim-
inated as a result of drug-induced cytotoxicity. This can be an
important cause of treatment failure (9). Moreover, cytotoxic
drugs can also promote active mechanisms of resistance induc-
tion. Thus, it has been shown that intermittent treatment of
mice bearing ovarian cancer xenografts with docetaxel led to the
development of different mechanisms of drug resistance, while
continuous drug infusion resulted in superior antitumor effi-
cacy and prevented drug resistance (10). These results suggested
that continuous drug infusion may have considerable advantages
over the more commonly used, intermittent, bolus administration
protocols (11).
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On the basis of these considerations it appeared of obvious
interest to elaborate mechanistic models that describe the effects
of continuous infusion on the tumor uptake of molecules com-
pared to bolus administration. We have performed such a study
taking advantage of a mechanistic tumor uptake model that had
been described for bolus administration (12). In this report we
describe the results of this study and compare them with those
obtained for bolus administration.
MATERIALS AND METHODS
Simulations were performed using the equations of the model
described by Schmidt and Wittrup (12), implemented in R (13)
and modified in its pharmacokinetic components in order to inte-
grate the intravenous administration rate. The model describes the
relationships between molecular radius (Rmol) and permeability
across the tumor capillary wall (P), diffusivity within the tumor
interstitium (D), available volume fraction in the tumor (ε), and
rate of plasma clearance (kclear), respectively. These relationships
are based on previously reported experimental measurements for
molecules of various sizes in tumor tissues [supplementary data
from Schmidt and Wittrup (12)].
The impact of molecular radius (Rmol) on diffusivity and avail-
able volume fraction was described by modeling tumor tissue as a
series of small and large right circular cylindric pores (14). Diffu-
sivity of molecules in each pore (Dporetum) can be estimated from
diffusivity in solution (Dfree) and the ratio (λ) of molecular radius
(Rmol) to pore radius (Rpore) using the equations:
Dporetum = Dfree
× 1− 2.105λ+ 2.0865λ
3 − 1.7068λ5 + 0.72603λ6
1− 0.78587λ5
Dfree =
3× 10−6cm2s
Rmol
forλ< 0.6. Forλ> 1, Dporetum= 0. For other values of λ, the ratio
Dporetum/Dfree was determined from previously described work
(15). Rmol is expressed in nanometers. Overall, diffusion within
the tumor is:
D = A × Dporetumsmall + B × Dporetumlarge
where A and B are the relative diffusions occurring in small and
large pores, respectively. According to this two-pore tumor model,
the available volume fraction is defined as:
ε = Vi
(
A × ϕporetumsmall + B × ϕporetumlarge
)
where V i is the interstitial fluid volume fraction [approximated
at 0.5 (16)], and partition coefficients for each pore size (ϕpore)
is (1−λ2) when λ< 1, and 0 when λ> 1 (17). Vascular perme-
ability was also modeled using a two-pore model of the capillary
wall, and transport was assumed to be mainly diffusive; therefore,
permeability across each pore was:
Pporecap = Dporecap × ϕporecap
Overall, total permeability was defined as:
P = Acap × Pporecapsmall + Bcap × Pporecaplarge
The impact of molecular size was modeled both on the renal
plasma clearance (CLR) and the non-renal plasma clearance
(CLNR). For non-renal plasma clearance, an empirical model
accounted for loss of molecules above the cutoff size for glomerular
filtration with an empirical model:
CLNR = CLNR,0 − δ Rmol
Rmol + γ
where CLNR,0 is the non-renal clearance for small molecule
tracers (set to 2 mL/h), and δ (mL/h) and γ (nm) are empir-
ical constants fit to the data. Renal plasma clearance is mod-
eled as CLR=GFR× θ where GFR is the glomerular filtration
rate (10 mL/h) and θ is the macromolecular sieving coefficient,
depending on molecular size:
θ = φKconv
1− e−σPe + φKconve−σPe
where Φ is the equilibrium partition coefficient, σ is a correction
term for the geometry of the glomerular slits approximately equal
to 2 for baseline glomeruli, K conv is the solute hindrance factor for
convection, and Pe is the Péclet number defined as:
Pe = φKconv × v × L
φKdiff × Dfree
where v is the fluid velocity vector (0.001 cm/s), L is the mem-
brane thickness [100 nm in mice (18)], and K diff is the diffusive
hindrance factor. K conv and K diff , along with the partition coeffi-
cient, are empirically modeled as (19)φKdiff = exp(−αRmol) and
φKconv = exp(−βRmol).
Plasma clearance (CL) was derived from renal and non-renal
components CL=CLR+CLNR, and along with plasma volume
V (2 mL in mice), constituted the pharmacokinetic parameters of
the one-compartment pharmacokinetic model.
Eventually, the tumor uptake was computed using a compart-
mental pharmacokinetic model in equilibrium with the tumor
interstitium and a drug/receptor binding model. Considering Ω
defined as:
Ω =
(
2PRcap
εR2Krogh
)(
Kd([
Ag
]
/ε
)− Kd
)
+ Ke
( ([
Ag
]
/ε
)([
Ag
]
/ε
)− Kd
)
the concentration in tumor after a single bolus administration is:
[AB]tumor =
(
2PRcap
R2Krogh
)Dose/Vplasma
(
e−kcleart − e−Ωt
)
(Ω− kclear)

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tumor concentration after intravenous infusion of rate,
Rate=Dose/T perf , when t >T perf is:
[AB]tumor =
∫ t
0
(
2PRcap
R2Krogh
)
×
Rate/Vplasma
(
e−kclear(t−u) − e−Ω(t−u)
)
(Ω− kclear)
 du
which can be rewritten as:
[AB]tumor =
(
2PRcap
R2Krogh
)
×
(
Rate/Vplasma
(Ω− kclear)
)(
1− e−kcleart
kclear
− 1− e
−Ωt
Ω
)
and tumor concentration after intravenous infusion of rate,
Rate=Dose/T perf , when t <T perf is:
[AB]tumor =
∫ Tperf
0
(
2PRcap
R2Krogh
)
×
Rate/Vplasma
(
e−kclear(t−u) − e−Ω(t−u)
)
(Ω− kclear)
 du
which can be rewritten as:
[AB]tumor =
(
2PRcap
R2Krogh
)(
Rate/Vplasma
(Ω− kclear)
)
×
 e − kcleart
(
ekclearTperf − 1
)
kclear
−
e−Ωt
(
eΩTperf − 1
)
Ω

where Dose is the amount of drug administered, t is the time,
[Ag] is the target antigen concentration (mol/L), ke is the rate of
endocytic clearance (s−1), K d is the affinity of the targeting mol-
ecule for the antigen (mol/L), Rcap is the capillary radius (µm),
and RKrogh is the average radius of tissue surrounding each blood
vessel (µm).
Simulations of tumor uptake versus time profiles were per-
formed for both intravenous bolus administration and continu-
ous infusion. Duration of continuous infusion T perf was set to
60 h with no loss of generality. The range of molecular radius
(Rmol) for simulations was set from 0.1 to 100 nm, and the
corresponding molecular weight (MW, expressed in kDa) was
approximated as MW = 1.32 × R3mol. The range of affinity for
the target (K d) for simulations was [10
−12; 10−6] (K d was set
to 10−9 when investigating tumor uptake/time relationship).
The case of IgG molecules is out of the scope of the present
work, as their plasma clearance is smaller than other molecules
with the same molecular weight due to their binding to FcRn
receptors (20).
Simulations were performed using estimated parameter values
described in Table 1, consistently with values used by Schmidt
and Wittrup (12). In order to better assess differences in tumor
Table 1 | Definition of the parameters and values used for simulations.
Parameter Definition Value
MW Molecular weight (kDa) 1–1000
Rtumsmall Radius of smaller tumor pore within tumor
(nm)
13.8
Rtumlarge Radius of larger tumor pore within tumor
(nm)
1000
Rcapsmall Radius of smaller tumor pore within capillary
wall (nm)
4.5
Rcaplarge Radius of larger tumor pore within capillary
wall (nm)
500
Atum Partition coefficient in smaller pores within
tumor (−)
0.9
Btum Partition coefficient in larger pores within
tumor (−)
0.1
Acap Partition coefficient in smaller pores within
capillary wall per unit membrane thickness
(cm−1)
17.6
Bcap Partition coefficient in larger pores within
capillary wall per unit membrane thickness
(cm−1)
0.65
V i Interstitial fluid volume fraction (−) 0.5
GFR Glomerular filtration rate (mL/h) 10
α Empirical fitting constant (nm−1) 1.6
β Empirical fitting constant (nm−1) 0.95
γ Empirical fitting constant (nm) 0.2
δ Empirical fitting constant (mL/h) 1.94
v Fluid velocity vector (cm/s) 0.001
L Membrane thickness (nm) 100
CLNR,0 Non-renal clearance for small molecules
tracers (mL/h)
2
Vplasma Plasma volume (mL) 2
σ Correction term for geometry of glomeruli (−) 2
Rcap Capillary radius 8
RKrogh Average radius of tissue surrounding blood
vessels (µm)
75
K d Molecule affinity for antigen (mol/L) 10−12–10−6
K e Rate of endocytic clearance (1/s) 0.000016
[Ag] Target antigen concentration in the tumor
(nmol/L)
1.5
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uptake between modes of administration, simulations were per-
formed both using the same administered dose (D) for bolus
administration and continuous infusion, and using D and 100×D
for bolus administration and continuous infusion, respectively.
Tumor uptake was expressed as a fraction of injected dose/gram
(% ID/g).
RESULTS
We simulated the influence of the molecular radius, the time-
course, and the affinity on the maximal tumor uptake of molecules
administered by continuous infusion. Duration of infusion was set
to 60 h.
The simulation of the influence of the molecular radius on
maximal tumor uptake (ID/g) showed (Figure 1A) that maximal
tumor uptake after continuous infusion was similar to that after
bolus administration for large molecules (Rmol > 3 nm), but it was
lower for small molecules (Rmol < 3 nm). The dose administered
by continuous infusion was then increased by a factor of 100 in
order to achieve a maximal tumor uptake (Figure 1B) for small
molecules similar to that after bolus administration. Under these
conditions, the reduced maximal tumor uptake of small mole-
cules after continuous infusion was no longer observed. Regarding
large molecules, the same pattern was observed after both modes
of administration (i.e., bolus and continuous), with an increase
to a maximal value of tumor uptake, and a decrease as molecules
exceeded a size of ∼10 nm.
FIGURE 1 | Maximal tumor uptake as a function of molecular radius
after continuous infusion (green) or bolus administration (red).
Administered dose is the same for both modes of administration in (A), but
is 100× higher for continuous infusion in (B).
The time-course of tumor uptake (Figures 2A,B) showed
that the increase in concentration was delayed after continuous
infusion compared to bolus administration, both for large and
small molecules. However, peak tumor uptake of small molecules
was more affected by the mode of administration than that of
large molecules, i.e., the increase in tumor uptake was higher for
small molecules than for large molecules. Regarding large mol-
ecules, while maximal tumor uptake was comparable between
bolus administration and continuous infusion, tumor exposure
was longer after continuous infusion. The benefit of a higher
maximal tumor uptake of small molecules observed after bolus
administration was balanced by the shorter duration of tumor
exposure.
Eventually, we investigated the relationship between affinity
and maximal tumor uptake (Figure 3). Increasing the affinity of
a molecule increased its maximal tumor uptake up to a plateau
value. This was seen for both bolus (Figure 3A) and contin-
uous infusion (Figure 3B). The affinity at which this plateau
value was attained depended for both modes of administration
on the size of the administered molecule (10−9 for larger mole-
cules, and 10−11 for smaller molecules). The fact that the affinity
required to achieve a similar tumor uptake is much lower for larger
than for smaller molecules shows that although the time-course
of tumor uptake is strongly dependent on the mode of admin-
istration, the relationship between tumor uptake and affinity is
unaffected.
DISCUSSION
In this article we have simulated the influence of molecular radius,
time-course, and affinity of a molecule (e.g., an antitumor drug)
on its maximal tumor uptake after continuous infusion and com-
pared the results with those obtained in a similar model after bolus
administration (12). For continuous infusion we set the duration
to 60 h, a time period sufficient to attain equilibrium between the
different compartments of the body.
We found that administration of a molecule by continuous
infusion led to a relatively homogeneous uptake, that was inde-
pendent of the molecular radius. A further increase of uptake, with
a bell-shaped curve, was observed for molecules with a radius of
∼5–20 nm, with a maximal uptake at ∼10 nm. This is likely due
to increased systemic accumulation of molecules that are larger
than the size allowing for elimination through kidney filtration.
Not surprisingly, at similar doses, maximal tumor uptake is much
higher for bolus administration than continuous infusion, but this
can be overcome by increasing the dose administered by contin-
uous infusion (in Figure 1B, the dose administered by infusion
is 100× higher than that administered by bolus). It is interest-
ing to note that the shape of the uptake curve upon continuous
infusion did not show the uptake minimum at ∼3 nm (25 kDa
molecular weight) that is observed after bolus administration. This
molecular size corresponds to that, for example, of a bispecific
single-chain variable fragment. A compound of this kind (blina-
tumomab) is now in advanced clinical trials for the treatment
of lymphoma acute lymphoblastic leukemia, and it is interesting
to note that it is administered to patients by continuous infu-
sion (21, 22). While lymphoma therapy is expected to suffer less
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FIGURE 2 |Tumor uptake (color scale, in % ID/g) as a function of time (x -axis) and molecular radius (y -axis) after bolus administration (A) or
continuous infusion (B) (same doses for both modes of administration).
from the impediments that characterize solid tumors, it appears,
nonetheless, that administration of agents of this molecular size
by continuous infusion is optimal to achieve the highest possi-
ble tumor uptake and accumulation. Overall, continuous infusion
appears to be preferable to bolus administration in view of the pos-
sibility of achieving a more predictable tumor uptake of molecules
of varying molecular size.
Also regarding the time-course of tumor uptake, continuous
infusion appears to present advantages compared to bolus admin-
istration, allowing for longer exposure of the tumor. For small
molecules, maximal tumor uptake was higher for bolus admin-
istration, but, again, this can be easily overcome by increasing
the dose administered by infusion. Eventually, the relationship
between tumor uptake and affinity of the administered mole-
cules appears to be independent of the mode of administra-
tion. Thus, in accordance with previous results obtained with
a similar model (12), the affinity required to achieve a similar
tumor uptake is much lower for larger than for smaller molecules,
and this is true for both bolus administration and continuous
infusion.
Overall, the results from the mechanistic model used in
this study suggest that continuous infusion offers some advan-
tages compared with the more commonly used bolus adminis-
tration. Most importantly, differences in uptake between mol-
ecules of different molecular size become less relevant upon
continuous infusion than bolus administration. In particular,
the nadir in tumor uptake at a ∼3 nm size disappears. More-
over, infusion allows for a prolonged exposure of tumor tis-
sues to both small- and large-sized molecules. Eventually, this
mode of administration may allow higher doses to be adminis-
tered by reducing Cmax-linked toxicity, thereby allowing a sim-
ilar maximal uptake compared to bolus administration. These
www.frontiersin.org July 2013 | Volume 3 | Article 192 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fouliard et al. Effect of infusion on tumor drug uptake
FIGURE 3 |Tumor uptake (color scale, in % ID/g) as a function of the affinity of the administered molecule for its receptor (x -axis) and molecular
radius (y -axis), 24 h after bolus administration (A) and at the end of a 60 h-continuous infusion (B) (same doses for both modes of administration).
advantages add to those related to reduced induction of drug
resistance as a consequence of more homogeneous distribution
of the drug throughout the tumor (10), thereby preventing or
limiting repopulation of the tumor by proliferating tumor cells
(9) and inhibiting induction of active mechanisms of resistance
induction (7).
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